News
-
-
PRESS RELEASE
Screening completed: Berlin Cures achieves key milestone in BC 007 Phase II Trial for treatment of Long COVID
Berlin Cures achieves key milestone in BC 007 Phase II trial for Long COVID treatment by successfully completing patient screening, marking a significant step in developing an effective therapy -
-
PRESS RELEASE
Racing Force Group: revenue at EUR 20.6 million in Q1 2024. Revenues from core business growing on a global scale. Particularly positive order collection in the quarter
Racing Force S.p.A. announces consolidated sales of €20.6 million in Q1 2024, with 5% growth excluding non-technical apparel orders. Sales mix shift observed in product categories and geographical regions -
-
PRESS RELEASE
Changement au sein de la direction de Valora Food Service: Sebastian Kayser et Sebastian Gooding succèdent à Thomas Eisele
Changements au sein de la direction de Valora Food Service : deux nouveaux CEO, Sebastian Kayser et Sebastian Gooding, succèdent à Thomas Eisele. Scission de la division Food Service en secteurs B2C et B2B -
PRESS RELEASE
3U’s e-commerce portal selfio.de again ranks in the “Top Shops” league of COMPUTER BILD and Statista
selfio.de, an e-commerce portal of 3U HOLDING AG, recognized as a top shop for home technology by COMPUTER BILD and Statista. Award highlights technical quality, user-friendliness, and product range -
PRESS RELEASE
SFC Energy AG: order from ConnectCom Sarl for delivery of stationary and mobile hydrogen fuel cell solutions for establishment of emergency power systems in the field of public safety in Luxembourg
SFC Energy AG receives order from ConnectCom Sarl for stationary and mobile hydrogen fuel cell solutions to establish emergency power systems in Luxembourg -
-
PRESS RELEASE
Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions d'euros dans le cadre de l'appel à projets " Innovations en Biothérapies et Bioproduction " de France 2030, pour développer un nouvel oligonucléotide antisens
Theranexus, Diverchim, and ARNA laboratory of INSERM receive 4.7 million euros from the French government to develop a groundbreaking autophagy activation therapy called PickASO
